Life Sciences Tools & Services
股价
$339.11
-4.61%市值
$23.28B
今日最高
$351.79
今日最低
$337.65
West Pharmaceutical Services (WST) delivered strong Q2 FY2026 results with revenue up 13.8% YoY to $872.3M and net income up 16.8% to $154.0M, driven by robust Proprietary Products demand (HVP components and delivery devices tied to GLP-1 and Biologics growth), though West Vantage segment profitability was pressured by a May 2026 cybersecurity incident.
关键风险:Cybersecurity attack causing operational disruption and financial exposure
In May 2026, the Company experienced a material cybersecurity attack in which data was exfiltrated and certain systems were encrypted, temporarily disrupting global operations and requiring the Company to proactively take systems offline worldwide for containment. Although the incident has been contained and operations have fully recovered, it contributed to nonrecurring professional fees and negatively impacted West Vantage revenue by approximately $7 million due to production downtime.
同属 Health Care Supplies 行业的其他公司